Back to School: How biopharma can reboot drug development. Access exclusive analysis here
MethylGene (TSX:MYG) and PHRM will collaborate to develop small molecule inhibitors targeting sirtuins, a class of
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury